Skip to main content

Table 3 Summary of results in patients on placebo

From: A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

Measurements Mean pre-placebo Mean post-placebo p value
Systolic BP (mmHg) 135 ± 13 128 ± 17 0.19
Diastolic BP (mmHg) 82 ± 7 78 ± 11 0.27
Total cholesterol (mmol/l) 4.31 ± 0.85 4.50 ± 1.06 0.57
HDL (mmol/l) 1.05 ± 0.34 1.06 ± 0.35 0.96
LDL (mmol/l) 2.42 ± 0.70 2.50 ± 0.96 0.80
Triglycerides (mmol/l) 2.11 ± 1.15 2.39 ± 1.42 0.55
HbA1c (mmol/mol) 50 ± 15 51 ± 15 0.92
Fructosamine (μmol/l) 257 ± 53 266 ± 64 0.67
HOMA-IR 3.1 ± 1.8 3.0 ± 1.4 0.86
∆RI-GTN (%) 24 ± 7 23 ± 6 0.58
∆RI-Salb (%) 9 ± 6 9 ± 6 0.98
sVCAM-1 (ng/ml) 705 ± 423 722 ± 423 0.91
cGMP (pmol/l) 177 ± 46 177 ± 59 0.98
Blood glutathione ratio 20 ± 12 21 ± 9 0.65
TAC (mM Asc [AEAC]) 0.43 ± 0.06 0.44 ± 0.07 0.62
hsCRP (mg/l) 3.2 ± 5.3 2.7 ± 2.7 0.72
ALT (iu/l) 51 ± 19 49 ± 26 0.86
AST (iu/l) 40 ± 15 41 ± 17 0.90
Mode ASQ (C2m) 99 ± 10 95 ± 13 0.44
  1. VSL#3® treated group n = 19; placebo treated group n = 16. Data expressed as mean and standard deviation. Four cGMP values were not measurable (3 from placebo group and 1 from VSL#3® group). HOMA-IR missing 1 value from each treatment group as insulin levels were outside the HOMA calculator range. HbA1c in the placebo group had one missing value. LDL cholesterol had missing data on 1 patient from placebo group and 1 from VSL#3® group as triglycerides were > 4.5 mmol/l which preclude LDL cholesterol calculation. SBP and DBP values were missing after intervention on 1 patient in the placebo group. Nineteen patients had completed ASQ (10 in VSL#3® group and 11 in placebo group). Missing data were excluded from respective analyses